Nature

TCF-1 upregulation identifies early innate lymphoid progenitors in the bone marrow

The cellular and molecular events that drive the early development of innate lymphoid cells (ILCs) remain poorly understood. We show that the transcription factor TCF-1 is required for the efficient ...
ascopubs.org

A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors.

First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with ...
Business Wire

FogPharma Announces First Patient Dosed in Phase 1/2 Clinical Trial of First-in-class TCF-blocking β-catenin Inhibitor, FOG-001, in Advanced Solid Tumors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma ®, a biopharmaceutical company committed to transforming the lives of patients through a new precision medicine approach widely applicable to important and ...